Tomivosertib

Phase 1Small molecule

EEffector Therapeutics

Tomivosertib is one of 54 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

Prolia

Amgen

Preclinical

14 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

MS Contin

Merck & Co.

Preclinical

2 5

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Active, not recruiting

Acute Myeloid Leukemia

NCT05744739

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Active, not recruiting·NNorthwestern University·Phase 1·NCT05744739·15 enrolled

PD-L1 Positive1 trial

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Active, not recruiting·EEffector Therapeutics·Phase 2·NCT04622007·68 enrolled

PDL-11 trial

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Completed·EEffector Therapeutics·Phase 2·NCT03616834·39 enrolled

Hematological Malignancies1 trial

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Terminated·EEffector Therapeutics·Phase 1/2·NCT02937675·28 enrolled

Breast Cancer1 trial

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer

Completed·TTranslational Research in Oncology·Phase 1·NCT04261218·19 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tomivosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tomivosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tomivosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Effector Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEffector Therapeutics

Tomivosertib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

PD-L1 Positive1 trial

PDL-11 trial

Hematological Malignancies1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News